SLDB Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$17.50median target· current $8.45 (+107.1%)14 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-1.920.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$858.5MSmall cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 2.29
- P/S (TTM)
- 3.65
- EV/EBITDA
- -3.69
Profitability & growth
- ROE (TTM)
- -57.4%
- Operating margin
- 0.0%
- Revenue growth YoY
- -100.0%
- Dividend yield
- —
- Beta
- 2.36
Last earnings
May 12, 2026 · Estimate $-0.44 · Reported $-0.52
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Solid Biosciences LLC
Company profileSolid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States. The company is headquartered in Cambridge, Massachusetts.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 500 RUTHERFORD AVENUE, CHARLESTOWN, MA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$858.5M
Shares outstanding$98.5M
52W high$11.45
52W low$3.79
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent